Molecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
Molecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025
Radio-DARPin療法（RDT）候選藥物MP0712得到在歐洲核醫學協會（EANM）大會上展示的體內數據支持；首批人體試驗預計將於2025年開始，初步臨床數據預計在2025年公佈
RDT strategic agreement with Orano Med revised and strengthened: both companies to co-develop four 212Pb-based RDT candidates, including MP0712
RDt與Orano Med的戰略協議經過修訂和強化：兩家公司將共同開發四種基於212Pb的RDt候選藥物，包括MP0712
MP0533 phase 1 dose escalation study continues; update to be presented at the American Society for Hematology Annual Meeting (ASH); protocol being amended to improve treatment exposure
MP0533相位1劑量遞增研究繼續進行；更新將在美國血液學年會（ASH）上呈現；爲改善治療效果正在修訂方案
CD3 Switch-DARPin proof-of-mechanism to be presented at the Society for the Immunotherapy of Cancer Annual Meeting (SITC); update on Switch-DARPin MP0621 to be presented at ASH
CD3 Switch-DARPin機制驗證將在免疫治療年會（SITC）上呈現；Switch-DARPin MP0621的更新將在ASH上呈現
MP0317 Phase 1 biomarker data presented at the International Cancer Immunotherapy Conference (CICON); additional biomarker data to be shared at SITC
MP0317相位1生物標誌數據在國際癌症免疫治療大會（CICON）上展示；額外生物標誌數據將在SITC上分享
Outlook: Funded into 2027 with cash and short-term time deposits of CHF 143.6 million as of September 30, 2024, Molecular Partners expects total operating expenses of CHF 65-70 million in 2024.
展望：截至2024年9月30日，Molecular Partners通過瑞士法郎14360萬現金及短期存款融資到2027年，預計2024年總營業費用爲6500-7000萬瑞士法郎
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the third quarter of 2024.
2024年10月31日（全球新聞社）——瑞士蘇黎世州茲里根（Zurich-Schlieren）和美國馬薩諸塞州康科德（Concord）——根據第53條收益法定規定的即時公告——臨床階段生物技術公司Molecular Partners AG（SIX：MOLN，納斯達克：MOLN）今天宣佈了2024年第三季度企業亮點和未經審計的財務業績
"In the last quarter we continued to execute our plan to bring our first Radio-DARPin program to IND submission, and into the clinics. DLL3 remains a highly interesting target that is gaining significant attention. Our team presented additional preclinical data showing that MP0712 is safe and efficacious in a highly relevant tumor model, with DLL3 expression levels matching those in human tumors," said Patrick Amstutz, Ph.D., Molecular Partners' Chief Executive Officer. "In addition, we strengthened our relationship with our partner Orano Med, ensuring that both parties will have the opportunity to bring two Radio-DARPin products to market, for a total of four. Lastly our recent capital raise allows us additional financial flexibility into 2027 with participation from new, specialized investors and supportive existing investors."
「在上個季度中，我們繼續執行計劃，推動我們的首個Radio-DARPin項目提交IND，並進入臨床試驗。 DLL3仍然是一個備受關注的高度有趣的靶點。我們的團隊展示了額外的臨床前數據，表明MP0712在極具相關性的腫瘤模型中安全有效，DLL3表達水平與人類腫瘤中的水平相匹配，」Molecular Partners首席執行官Patrick Amstutz博士表示。 「此外，我們與合作伙伴Orano Med的關係得到加強，確保雙方將有機會推出兩種Radio-DARPin產品，共計四種。最近的資本增資使我們在擁有來自新的專業投資者和支持性現有投資者的參與下，進一步提高了2027年的財務靈活性。」
